- Home
- REGN vs MET Comparison
REGN vs MET Comparison
Compare REGN & MET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- MET
- Stock Information
- Founded
- REGN 1988
- MET 1863
- Country
- REGN United States
- MET United States
- Employees
- REGN N/A
- MET N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- MET Life Insurance
- Sector
- REGN Health Care
- MET Finance
- Exchange
- REGN Nasdaq
- MET Nasdaq
- Market Cap
- REGN 59.9B
- MET 53.2B
- IPO Year
- REGN 1991
- MET N/A
- Fundamental
- Price
- REGN $558.87
- MET $73.97
- Analyst Decision
- REGN Buy
- MET Strong Buy
- Analyst Count
- REGN 21
- MET 10
- Target Price
- REGN $823.86
- MET $96.10
- AVG Volume (30 Days)
- REGN 940.4K
- MET 2.9M
- Earning Date
- REGN 08-01-2025
- MET 08-06-2025
- Dividend Yield
- REGN 0.63%
- MET 3.07%
- EPS Growth
- REGN 5.03
- MET 112.38
- EPS
- REGN 39.67
- MET 6.14
- Revenue
- REGN $14,214,200,000.00
- MET $73,494,000,000.00
- Revenue This Year
- REGN N/A
- MET $7.25
- Revenue Next Year
- REGN $6.65
- MET $3.69
- P/E Ratio
- REGN $14.09
- MET $12.06
- Revenue Growth
- REGN 5.38
- MET 8.77
- 52 Week Low
- REGN $476.49
- MET $65.21
- 52 Week High
- REGN $1,211.20
- MET $89.05
- Technical
- Relative Strength Index (RSI)
- REGN 54.16
- MET 35.64
- Support Level
- REGN $541.61
- MET $74.27
- Resistance Level
- REGN $563.59
- MET $78.98
- Average True Range (ATR)
- REGN 15.37
- MET 1.50
- MACD
- REGN -0.75
- MET -0.31
- Stochastic Oscillator
- REGN 41.57
- MET 15.94
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About MET MetLife Inc.
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.